Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 18 of 18 publications.

Starzyk K, Hoffman V, Su Z, Meng R, Bhartia M, Curhan G, Yoshida K, Paulus JK. More than half of patients with a rheumatic disease or immunologic condition undergoing methotrexate treatment reside in states in which the overturning of Roe v. Wade can jeopardize access to medications with abortifacient potential. Arthritis Rheumatol. 2023 Feb;75(2):328-9. doi: 10.1002/art.42398

Urowitz M, Georgiou ME, Su J, MacKinnon A, Green Y, Gairy K, Levy RA, Juliao PC. Long-term renal survival of patients with LN by renal response status in the Toronto lupus cohort. Poster presented at the American College of Rheumatology (ACR) Annual Meeting; November 14, 2022. Philadelphia, PA. [abstract] Arthritis Rheumatol. 2022; 74(Suppl 9).

Bell CF, Meyers J, Ajmera M. Incremental healthcare costs of Eosinophilic Granulomatosis with Polyangiitis (EGPA) compared to asthma: retrospective analysis of commercial claims data in the United States (US). Poster presented at the 2021 Virtual American College of Rheumatology (ACR) Convergence; November 6, 2021. [abstract] Arthritis Rheumatol. 2021; 73(Suppl 10).

Mazurek M, Halperin JL, Huisman MV, Diener HC, Dubner SJ, Ma CS, Rothman KJ, Healey JS, Teutsch C, Paquette M, Franca LR, Lu S, Bartels DB, Lip GYH. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. Europace. 2020 Jan 1;22(1):47-57. doi: 10.1093/europace/euz278

Doyle S, Moss E, Hartley L, Knight C, Bell J, Ahdesmaki O, Kelly M. An economic systematic literature review of eosinophilic granulomatosis with polyangiitis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1953. doi: 10.1002/art.40700

Doyle S, Njue A, Lyall M, Rushton R, Heyes A, Kelly M. Systematic review of the clinical effectiveness of treatments in eosinophilic granulomatosis with polyangiitis. Poster presented at the 2018 ACR/ARHP Annual Meeting; October 22, 2018. Chicago, IL. [abstract] Arthritis Rheumatol. 2018 Sep; 70(S9):1944. doi: 10.1002/art.40700

Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 Jul;16(3):377-87. doi: 10.1007/s10689-017-9972-2

Hoffman E, Mladsi DM, Cryer B, Hopkins W, Brater DC, Parikh R, Goyal R, Castellsague J, Stafkey-Mailey D, Young C. Dose-related risks of cardiovascular, gastrointestinal, and renal adverse events associated with meloxicam among patients with osteoarthritis: an observational study using US claims data. Poster presented at the 2016 ACR/ARHP Annual Meeting; November 15, 2016. Washington, DC. [abstract] Arthritis Rheumatol. 2016 Sep 28; 68(Suppl 10).

Huisman MV, Ma CS, Diener HC, Dubner SJ, Halperin JL, Rothman KJ, Teutsch C, Schoof N, Kleine E, Bartels DB, Lip GY. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) phase I cohort. Europace. 2016 Sep;18(9):1308-18. doi: 10.1093/europace/euw073

Gossec L, Kvien TK, Conaghan PG, Ostergaard M, Canete JD, Gaillez C, Mpofu S, Sherif B, Jugl S. Relationship between improvements in fatigue and signs & symptoms of active psoriatic: arthritis a sub-analysis of a phase 3 study with secukinumab. Poster presented at the 2015 ACR/ARHP Annual Meeting; November 10, 2015. San Francisco, CA. [abstract] Arthritis Rheumatol. 2015 Sep 29; 67(Suppl 10).

Druce KL, Jones GT, Macfarlane GJ, Basu N. Determining pathways to improvements in fatigue in rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Arthritis Rheumatol. 2015 Sep;67(9):2303-10. doi: 10.1002/art.39238

Accortt N, Anthony MS, Schenfeld J, Wheeling T, Hassebroek A, O'Malley CD, Sprafka M. Incidence and prevalence of myasthenia gravis in rheumatoid arthritis patients with and without treatment compared with the general population. Poster presented at the 2014 ACR/ARHP Annual Meeting; November 2014. Boston, MA. [abstract] Arthritis Rheumatol. 2014 Oct; 66(Suppl 1):S895.

Wolowacz SE, Samuel M, Brennan VK, Jasso-Mosqueda J, Van Gelder IC. The cost of illness of atrial fibrillation: a systematic review of the recent literature. Europace. 2011 Oct 1;13(10):1375-85.

Huang K, Gutierrez LP, Bulow S, Gallinger S, Castells A, Eagle CJ, Church JM. Clinical characteristics and outcomes in familial adenomatous polyposis patients with a long-term treatment of celecoxib: a matched cohort study. Fam Cancer. 2011 Jun 1;10(2):303-8.

Smith VK, Evans MF, Banzhaf HS, Poulos C. Can weak substitution be rehabilitated? Environ Resour Econ (Dordr). 2010 Feb 1;45(2):203-21.

Poole WK, Pollack M, Rapoport I, Williams V, Koch MA, Rao AV, Bartel DA. Use of Multivariate Methods in Quantifying the Variability in the Perception of Neonatal Intensive Care Unit Characteristics in Nine Hospitals in the Washington, DC Area: the NIH-DC Initiative to Reduce Infant Mortality in Minority Populations in the District of Columbia. Interstat. 2002 Jan 1.

Helliwell PS, Doward L, Whalley D, Tennant A, McKenna S, Reynolds S, Kay L, Spoorenberg A, van der Heijde Leeds D. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis (AS). Poster presented at the 1999 ACR/ARHP Annual Scientific Meeting; November 14, 1999. Boston, MA. [abstract] Arthritis Rheumatol. 1999 Sep; 42(S9):s72.

Mansfield CA. Despairing over disparities: an empirical analysis of the relationship between willingness-to-pay and willingness-to-accept. Environ Resour Econ (Dordr). 1999;13(2):219-34.